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To define whether the association of male lower urinary tract symptoms (LUTS) and metabolic syndrome (MS) is real or simply an
epiphenomenon, 490 male adults (mean age 58 ± 9 years) underwent International Prostate Symptom Score (IPSS), physical and
prostate digital examinations, blood analysis, and urinary tract transabdominal ultrasound with prostate volume measurement.
Mild, moderate, and severe LUTS were found in 350 (71.4%), 116 (23.7%), and 24 (4.9%) patients, respectively. MS was present in
198 (40.4%) patients, representing 37.4% (131 of 350) of those with mild LUTS, 46.5% (54 of 116) of those with moderate, and 54.1%
(13 of 24) of those with severe. The odds ratio of MS having moderate or severe LUTS was 2.1. MS was more common in older age,
higher body mass index, and larger prostate size. Moderate and severe LUTS were more frequent in older age, lower levels of high
density cholesterol, and higher blood pressure. Older age and body mass index had significant relative risk for lower urinary tract
symptoms and only age remained independent factor for LUTS on multivariate analysis. Our results suggest that the association of
male LUTS, prostate volume, and MS might be coincidental and related to older age.
1. Introduction
Lower urinary tract symptoms (LUTS) in old men are gen-
erally attributed to benign prostatic enlargement (BPE) and
may be associated with metabolic syndrome (MS) [1] due to
several putative hormonal pathways that may lead to both
conditions [2]. BPE and MS are highly prevalent diseases
especially in the aged population [3, 4] leading to doubt
whether the association of these conditions is real or simply
an epiphenomenon.
This study aims to correlate male lower urinary tract
symptoms, prostate volume, and metabolic syndrome.
2. Methods
2.1. Population. After exclusion of patients with previous
prostate or urethral operations (𝑛 = 11), we studied 490
unselected and consecutive male adults, of mean age 58 ± 9
(36–84) years, from an institutional review board approved
prospectively kept database originated from a community
hospital general urologic clinic in a cross-sectional study.
All individuals were routinely questioned, at the time of
the first consultation, in regards to lower urinary tract symp-
toms, and had a full physical examination, prostate digital
rectal examination, blood collected for laboratory analysis,
and a baseline urinary tract transabdominal ultrasound with
prostate volume measurement.
2.2. Male Lower Urinary Tract Symptoms. Male LUTS were
defined based on the International Prostate Symptom Score
(IPSS).The score ranges from0 to 35. A score of 0–7 is defined
asmildly symptomatic, 8–19 asmoderately symptomatic, and
20–35 as severely symptomatic [5].
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Table 1: Demographic parameters of patients according to the presence of metabolic syndrome.
Continuous variables Metabolic syndrome (𝑛 = 198) Nonmetabolic syndrome (𝑛 = 292) P
Age (years) 59 ± 9 57 ± 9 0.02
Body mass index (Kg/m2) 30 ± 4 26 ± 4 <0.001
Prostate volume (cm3) 31 ± 9 29 ± 8 0.01
Total PSA 1.69 ± 4.1 1.49 ± 4.0 0.30
Total testosterone (ng/dL) 486 ± 250 512 ± 251 0.26
Free testosterone (ng/dL) 90 ± 66 97 ± 67 0.25
IPSS 5 ± 7 7 ± 7 0.12
PSA: prostate specific antigen; IPSS: International Prostatic Symptoms Score.
Data in bold font refers to P value <0.05.
2.3. Metabolic Syndrome. MS was defined based on the US
National Cholesterol Education Program Adult Treatment
Panel III, 2001 [6].
2.4. Statistics. Variables are expressed as mean ± standard
deviation (range).
Student’s t-test, odds ratio (confidence interval), relative
risk (confidence interval), and logistic regression were used
when indicated. Multivariate analysis (bias-reduced logistic
regression) considered presence of mild versus moderate +
severe LUTS as the dependent variable. Statistical power was
calculated comparing the proportions of LUTS and MS with
a tolerated alpha error level of 5%.
The two-sided value of 𝑃 < 0.05 was considered
significant.
3. Results
Mild, moderate, and severe LUTS were found in 350 (71.4%),
116 (23.7%), and 24 (4.9%) patients, respectively. Overall, MS
was present in 198 (40.4%) patients, representing 37.4% (131
of 350) of those with mild LUTS, 46.5% (54 of 116) of those
with moderate, and 54.1% (13 of 24) of those with severe
LUTS.
The odds ratio of patients with MS having moderate or
severe LUTS was 2.1 (95% CI = 1.41 to 3.13) with a statistical
power of 98.6%.
Table 1 shows demographic and prostatic parameters of
patients according to the presence of metabolic syndrome.
MS was more common in older age, higher body mass index,
and larger prostate size.
Table 2 shows demographic and metabolic parameters
of patients according to lower urinary tract symptoms.
Moderate and severe LUTS were more frequent in older
age, lower levels of high density cholesterol, higher blood
pressure, and higher prostate volume.
Table 3 shows the relative risk for lower urinary tract
symptoms based on metabolic parameters. Only older age
and higher body mass index were significant risks for lower
urinary tract symptoms.
Only age remained as an independent factor for lower
urinary tract symptoms after multivariate analysis (Table 4).
4. Discussion
Considering the potential for preventive public health atti-
tudes, it is important to predict the events leading to LUTS
and BPE progression and recent studies have suggested a
possible association between the metabolic syndrome and
the occurrence of LUTS/BPE, with possible new targets for
prevention and treatment of these disorders, although the
evidence for a causal relationship remains missing [7].
Our results show that (1) MS brings a 2-fold risk for male
lower urinary tract symptoms, (2) older age and body mass
index are risk factors for male lower urinary tract symptoms,
and (3) older age, lower levels of high density cholesterol,
and higher blood pressure are risk factors for moderate and
severe LUTS; however, only age remained as an independent
factor for male lower urinary tract symptoms onmultivariate
analyses.
4.1. Correlation among Male Lower Urinary Tract Symptoms,
MS, Prostate Volume, and Age. The correlation betweenmale
lower urinary tract symptoms andMS is a controversial topic.
While some authors advocate a link between the diseases
[8, 9] others have not found this association significant [10–
13]. LUTS in old men are generally attributed to BPE [1] and
BPE may be related to MS [14]. In fact, our results show
that MS is more common in patients with larger prostates,
even though benign prostatic hyperplasia (BPH) was not
confirmed by biopsy. Thus, we have limited our evaluation
to BPE, a clinical entity representing the pathological entity
BPH. Age may be the essential mutual factor between MS
and LUTS since both conditions are prevalent in the elderly
population. Severe LUTSmay be found in 10% of males older
than 70 years [15] and 52% of males 60 years and over will
have MS in the United States [16].
Our results showed some risk factors simultaneously for
MS and male lower urinary tract symptoms. However, older
age is also a common feature for these putative risk factors.
Higher body mass index has been described as a common
pathway between male lower urinary tract symptoms and
MS [17]. The prevalence of obesity increases with age [18].
Similarly, low levels of high density cholesterol are common
in the elderly [19] and a mutual characteristic of MS and
male lower urinary tract symptoms [20]. Finally, high blood
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Table 2: Demographic and metabolic parameters of patients according to lower urinary tract symptoms (IPSS).
Continuous variables Mild (𝑛 = 350) Moderate (𝑛 = 116) Severe (𝑛 = 24) P
Age (years) 56 ± 8 61 ± 8 63 ± 9
Mild versus moderate <0.001
Mild versus severe <0.001
Moderate versus severe = 0.3
Body mass index (Kg/m2) 28 ± 5 28 ± 5 28 ± 4 1
Abdominal circumference (cm) 98 ± 10 100 ± 11 97 ± 11
Mild versus moderate 0.07
Mild versus severe 0.6
Moderate versus severe 0.2
Triglycerides (mg/dL) 153 ± 104 152 ± 89 117 ± 62
Mild versus moderate 0.9
Mild versus severe 0.09
Moderate versus severe 0.07
Cholesterol (mg/dL) 193 ± 40 192 ± 39 184 ± 31
Mild versus moderate 0.8
Mild versus severe 0.3
Moderate versus severe 0.3
High density cholesterol (mg/dL) 44 ± 15 40 ± 12 37 ± 15
Mild versus moderate 0.01
Mild versus severe = 0.03
Moderate versus severe 0.3
Glycemia (mg/dL) 108 ± 37 113 ± 41 103 ± 26
Mild versus moderate 0.2
Mild versus severe 0.5
Moderate versus severe 0.2
Systolic blood pressure (cmHg) 12 ± 1 13 ± 1 13 ± 1
Mild versus moderate <0.001
Mild versus severe <0.001
Moderate versus severe 1
Diastolic blood pressure (cmHg) 8 ± 1 8 ± 1 9 ± 1
Mild versus moderate 1
Mild versus severe <0.001
Moderate versus severe <0.001
Prostate volume (cm3) 29 ± 9 33 ± 9 33 ± 10
Mild versus moderate <0.001
Mild versus severe 0.04
Moderate versus severe 1
Data in bold font refers to P value <0.05.
Table 3: Relative risk for lower urinary tract symptoms based on demographic and metabolic parameters.
Categorical variables LUTS mild (𝑛 = 350) LUTS moderate/severe (𝑛 = 140) Relative risk (95% CI)
Age > 60 years 125 (36%) 133 (95%) 17.08 (8.16 to 35.78)
BMI > 30 kg/m2 91 (26%) 137 (98%) 52.48 (16.95 to 162.46)
AC > 102 cm 91 (26%) 40 (28%) 1.10 (0.81 to 1.49)
TG > 150mg/dL 137 (39%) 47 (33%) 0.84 (0.62 to 1.13)
HDL < 40mg/dL 141 (40%) 74 (53%) 1.43 (1.08 to 1.90)
Gly > 110mg/dL 88 (25%) 39 (28%) 1.10 (0.81 to 1.50)
SBP > 13 cmHg 136 (39%) 80 (57%) 1.69 (1.27 to 2.24)
DBP > 8 cmHg 107 (30%) 56 (40%) 1.34 (1.00 to 1.77)
Prostate > 40 cm3 89 (25%) 50 (36%) 1.40 (1.05 to 1.86)
LUTS: lower urinary tract symptoms; BMI: body mass index; AC: abdominal circumference; TG: triglycerides; HDL: high density cholesterol; Gly: glycemia;
SBP: systolic blood pressure; DBP: diastolic blood pressure.
pressure shares the same characteristic of high prevalence
with advanced age [19]; this also happens in male patients
with lower urinary tract symptoms and MS [21].
After adjusting for age and testosterone, there was no
association between MS and male lower urinary tract symp-
toms measured by the previously validated tool IPSS in our
series of Latin American patients. To add controversy to
the issue, metabolic syndrome was also previously described
as having favorable effects on male lower urinary tract
symptoms [9, 22]. Compared to the non-MS group, men
in the MS group were less likely to experience moderate to
severe LUTS elsewhere (OR 0.58, 95% CI 0.41–0.83) [9].
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Table 4: Multivariate analysis for the presence of mild versus mod-
erate + severe male LUTS as the dependent variable.
Variables P value
Age <0.001
Body mass index 0.4
Total cholesterol 0.4
High density cholesterol 0.4
Low density cholesterol 0.2
Triglycerides 0.7
Glycemia 0.7
Systolic blood pressure 0.1
Diastolic blood pressure 0.7
Abdominal circumference 0.3
Data in bold font refers to P value <0.05.
4.2. Study Limitations. Our study has some potential lim-
itations. First, this is a retrospective case series from a
community hospital; nonetheless, a significant number of
patients were included in the study bringing an effective
statistic power. Also, the prevalence of MS in Brazil is high
[23], 40.4% in our study, favoring the proposed comparison
betweenMS andmale lower urinary tract symptoms. Second,
prostate biopsy was not available for most patients to allow
the precise diagnosis of BPH in order to correlate LUTS
and BPH; alternatively we focused on prostate volume or
BPE, which represents virtually all BPH. Additionally, the
previously validated IPSS (male LUTS) is a more reliable
and precise tool, figuring as a key outcome on the subject
considering its accuracy to determine the main impact of
BPH or causative factors on patients’ quality of life, which is
what really matters.
Finally, considering the debatable literature on the issue
[8–10, 13, 14, 22] and the fact that most studies to date
come from Asia where metabolic syndrome incidence is as
low as 10–20% compared to over 40% in the present study,
report of every series is important to add knowledge to this
controversial subject, especially a Latin American series.
5. Conclusions
Our results show that the association of male lower urinary
tract symptoms, prostate volume, and MS may be coinciden-
tal and related to older age.
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